Placeholder Banner

BIO Statement on Release of USTR’s 2017 “Special 301 Report”

May 1, 2017

Washington, D.C. (May 1, 2017) – The Biotechnology Innovation Organization (BIO) issued the following statement today:

“BIO welcomes the release of USTR’s 2017 Special 301 Report on Intellectual Property Rights. The United States leads the world in global biotech research and innovation, and relies on the strong protection of intellectual property rights globally to maintain the engine of innovation. U.S. bioscience industries employed 1.66 million people in 2014 across more than 77,000 U.S. business establishments. The broader employment impact of U.S. bioscience jobs is an additional 7.53 million jobs throughout the
rest of the economy. Taken together, these direct, indirect, and induced bioscience jobs account for a total employment impact of 9.2 million jobs. 

“The research and development of cutting edge pharmaceutical, agricultural, industrial, and environmental biotechnology products requires substantial capital, involves long time frames, and is inherently risky.  The vast majority of BIO’s roughly 1000 members are small- and medium-sized enterprises that currently do not have products on the market.  As such, BIO’s members rely heavily on the strength and scope of their intellectual property (IP) to generate investments needed to develop and commercialize their technologies.

“USTR’s 2017 report addresses many of the key IP-related challenges that BIO members face globally, including inadequate legal protections, enforcement issues, restrictive patentability criteria, lengthy patent backlogs, and the threat of outright expropriation of U.S. intellectual property rights through compulsory licensing.  

“The promise of biotechnology is that it can address some of the biggest challenges facing mankind, including health, hunger, and environmental protection. While stronger IP laws and policies in foreign markets help BIO members do business abroad, a commitment to stronger IP also works to increase the global incentives for biotech research and investment, including investments in countries seeking to foster innovation in biosciences.”

###

Discover More
Seed technology companies comply with Mexico’s biosafety regulations, and Mexico should do the same, BIO said today in its response to the panel set up to determine if Mexico’s ban on imports of genetically modified corn violate its commitments…
BIO President & CEO John F. Crowley announced today that BIO would take several important steps to reaffirm the organization’s position with regards to national security and the role that the industry plays as a vital strategic asset: “As a…
Following the conclusion of the WTO 13th Ministerial Conference in Abu Dhabi, John Murphy -- BIO's Chief Policy Officer -- made the following statement: “We are encouraged that WTO Members did not agree to extend an intellectual property…